论文部分内容阅读
目的:比较贝那普利联合硝苯地平控释片与贝那普利联合氢氯噻嗪对高危高血压患者血压控制率和心血管发病率/死亡率的影响。方法:选择100例原发性高血压患者进行随机分组,A组:贝那普利联合硝苯地平控释片;B组:贝那普利联合氢氯噻嗪。用药后第2周、第1,2,6,12个月分别进行随访,比较降压疗效及对心血管发病率和死亡率的影响。结果:A组血压达标率为85.3%,B组血压达标率为79.6%,两者差异有显著性(P<0.05);且前者较后者可显著降低心血管发病率、死亡率(P<0.05)。结论:贝那普利联合硝苯地平控释片无论从降压效果还是降低心血管发病率/死亡率上都优于贝那普利联合氢氯噻嗪。
Objective: To compare the effects of benazepril combined with nifedipine GITS and benazepril combined with hydrochlorothiazide on blood pressure control rate and cardiovascular morbidity / mortality in high-risk hypertensive patients. Methods: One hundred patients with essential hypertension were randomly divided into group A: benazepril combined with nifedipine controlled release tablets; and group B: benazepril combined with hydrochlorothiazide. Week 2, 1, 2, 6 and 12 months after treatment were followed up to compare the effect of antihypertensive treatment and cardiovascular morbidity and mortality. Results: The blood pressure compliance rate was 85.3% in group A and 79.6% in group B. The former was significantly lower than the latter in cardiovascular morbidity and mortality (P < 0.05). CONCLUSION: The combination of benazepril and nifedipine is superior to benazepril and hydrochlorothiazide in terms of antihypertensive efficacy and cardiovascular morbidity / mortality.